Dry eye disease and proteomics.

Dry eye disease (DED) is a highly prevalent disease worldwide mostly associated with age, though other factors such as screen use and contact lens wear explain why it is increasingly diagnosed in younger people. DED also disproportionately affects women. Symptoms include eye dryness, burning, pain and sensitivity to light that can significantly affect quality of life. This condition may progress to cause lasting damage to the ocular surface if left untreated. Currently, diagnosis is through assessment of signs and symptoms determined by clinical tests and questionnaires. However, there is considerable overlap between normal and DED result distributions of currently available metrics as signs and symptoms fluctuate over time and with disease severity. Importantly, the non-targeted approach of proteomics means that significant changes in novel proteins may be discovered. Proteomics is a powerful tool that has been applied to the field of DED to understand changes at a biochemical level, uncover new disease biomarkers and determine the success of clinical interventions. While individual proteins may not be sensitive enough when used as single biomarkers, proteomics opens the possibility to uncover several relevant proteins that may be combined in a panel to provide more accurate diagnostic value i.e. parallel testing. In this review we discuss the use of proteomics in DED research and the potential for application of proteomic results in the clinic. We also identify shortcomings and future avenues for research.